Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedImmune Plans To Expand Sales Force As It Reacquires Synagis Promotion Rights

This article was originally published in The Pink Sheet Daily

Executive Summary

Abbott will release co-promotion rights for the respiratory syncytial virus therapy effective June 30, 2006.

You may also be interested in...



MedImmune To Release Phase III Data By Year-End For Synagis Follow-On

MedImmune is on track to launch the newest member of its respiratory syncytial virus therapy franchise for the 2008–2009 respiratory virus season.

MedImmune To Release Phase III Data By Year-End For Synagis Follow-On

MedImmune is on track to launch the newest member of its respiratory syncytial virus therapy franchise for the 2008–2009 respiratory virus season.

Supreme Court To Hear MedImmune Patent Case Against Genentech

MedImmune’s suit challenges the validity of the Cabilly patent, which it licenses from Genentech.

Related Content

Topics

UsernamePublicRestriction

Register

PS062821

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel